| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia
|
Even, C.
|
|
2014
|
50 |
12 |
p. 2082-2089
8 p.
|
artikel
|
| 2 |
An (only) partially established paradigm of drug development of targeted therapies
|
Rodon, Jordi
|
|
2014
|
50 |
12 |
p. 2037-2039
3 p.
|
artikel
|
| 3 |
A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer
|
Powles, Thomas
|
|
2014
|
50 |
12 |
p. 2057-2064
8 p.
|
artikel
|
| 4 |
A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma
|
Carvajal, Richard D.
|
|
2014
|
50 |
12 |
p. 2099-2107
9 p.
|
artikel
|
| 5 |
A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas
|
Infante, Jeffrey R.
|
|
2014
|
50 |
12 |
p. 2072-2081
10 p.
|
artikel
|
| 6 |
Blood 25-hydroxyvitamin D levels and overall mortality in patients with colorectal cancer: A dose–response meta-analysis
|
Wang, Bin
|
|
2014
|
50 |
12 |
p. 2173-2175
3 p.
|
artikel
|
| 7 |
BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients – A study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)
|
Ruscito, I.
|
|
2014
|
50 |
12 |
p. 2090-2098
9 p.
|
artikel
|
| 8 |
Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events
|
Ewer, Michael S.
|
|
2014
|
50 |
12 |
p. 2162-2170
9 p.
|
artikel
|
| 9 |
Decreased toxicity with 2 weeks on and 1 week off schedule of sunitinib in metastatic renal cell carcinoma: Is it a mirage or an oasis?
|
Malik, Laeeq
|
|
2014
|
50 |
12 |
p. 2171-2172
2 p.
|
artikel
|
| 10 |
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: Results of a DLT-TARGETT international survey
|
Paoletti, Xavier
|
|
2014
|
50 |
12 |
p. 2050-2056
7 p.
|
artikel
|
| 11 |
Diabetes and cancer: 5years into the recent controversy
|
Badrick, Ellena
|
|
2014
|
50 |
12 |
p. 2119-2125
7 p.
|
artikel
|
| 12 |
Diabetes mellitus increases the risk of early gastric cancer development
|
Sekikawa, Akira
|
|
2014
|
50 |
12 |
p. 2065-2071
7 p.
|
artikel
|
| 13 |
Measurement or estimation of glomerular filtration rate in seminoma patients: Quite another cup of tea
|
Fehr, Martin
|
|
2014
|
50 |
12 |
p. 2176-2177
2 p.
|
artikel
|
| 14 |
Response to: ‘Letter to the editor, European Journal of Cancer’, commenting on ‘Performance of formulae based estimates of glomerular filtration rate for carboplatin dosing in stage 1 seminoma’
|
Shepherd, Scott T.C.
|
|
2014
|
50 |
12 |
p. 2178-2179
2 p.
|
artikel
|
| 15 |
Review of therapeutic drug monitoring of anticancer drugs part 1 – Cytotoxics
|
Paci, Angelo
|
|
2014
|
50 |
12 |
p. 2010-2019
10 p.
|
artikel
|
| 16 |
Review of therapeutic drug monitoring of anticancer drugs part two – Targeted therapies
|
Widmer, Nicolas
|
|
2014
|
50 |
12 |
p. 2020-2036
17 p.
|
artikel
|
| 17 |
Risk of subsequent cancers in renal cell carcinoma survivors with a family history
|
Chen, Tianhui
|
|
2014
|
50 |
12 |
p. 2108-2118
11 p.
|
artikel
|
| 18 |
Significant survival impact of MACC1 polymorphisms in HER2 positive breast cancer patients
|
Muendlein, Axel
|
|
2014
|
50 |
12 |
p. 2134-2141
8 p.
|
artikel
|
| 19 |
The complement receptors CD46, CD55 and CD59 are regulated by the tumour microenvironment of head and neck cancer to facilitate escape of complement attack
|
Kesselring, Rebecca
|
|
2014
|
50 |
12 |
p. 2152-2161
10 p.
|
artikel
|
| 20 |
The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis
|
Alexandre, David
|
|
2014
|
50 |
12 |
p. 2126-2133
8 p.
|
artikel
|
| 21 |
Therapeutic drug monitoring in cancer – Are we missing a trick?
|
Bardin, Christophe
|
|
2014
|
50 |
12 |
p. 2005-2009
5 p.
|
artikel
|
| 22 |
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents – Dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led study
|
Postel-Vinay, Sophie
|
|
2014
|
50 |
12 |
p. 2040-2049
10 p.
|
artikel
|
| 23 |
Transport and Golgi organisation protein 1 is a novel tumour progressive factor in oral squamous cell carcinoma
|
Sasahira, Tomonori
|
|
2014
|
50 |
12 |
p. 2142-2151
10 p.
|
artikel
|
Tijdschrift beschrijving